Real-World Implementation of Molecular Testing and Biomarker-Guided Therapies in HR+/HER2− Metastatic Breast Cancer
- 1Department of Obstetrics and Gynecology, Division of General Gynecology and Gynecologic Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria
- 2Department of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria
Abstract
Background/Objectives: The introduction of biomarker-guided therapies, including PI3K, AKT and PARP inhibitors as well as Selective Estrogen Receptor Degraders (SERDs), has expanded treatment options and delayed the need for chemotherapy in hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC). Nevertheless, evidence regarding their implementation in routine clinical practice remains limited. This study evaluated the real-world use of molecular testing and biomarker-guided therapies in patients with HR+/HER2− mBC. Methods: Patients with HR+/HER2− mBC treated at the Medical University of Vienna, Austria, between July 2020 (EMA approval of alpelisib, marking the introduction of biomarker-guided therapies in HR+/HER2− mBC) and April 2025 were identified through a retrospective chart review. Patient and disease characteristics, molecular testing patterns, utilization of biomarker-guided therapies, and oncological outcome were assessed. Biomarker-guided therapies included alpelisib and capivasertib for PI3K/AKT pathway alterations, elacestrant for ESR1 mutations, and PARP inhibitors for BRCA1/2 mutations. Descriptive statistics summarized patient characteristics, molecular testing, and biomarker-guided therapies. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and prognostic factors were evaluated using univariable and multivariable Cox regression analyses. Results: A total of 274 patients with HR+/HER2− mBC were included. 63.5% (174/274) of patients had undergone at least one molecular test. Overall, 59.8% (104/174) of patients harbored at least one actionable molecular alteration. Of these, 54.8% (57/104) received a biomarker-matched therapy. Of the 47 patients who had not received a matched therapy, 25 remained on first-line CDK4/6 inhibitor-based treatment and were therefore not yet candidates for subsequent biomarker-guided therapy. 12.8% (6/47) of patients with a targetable alteration did not receive a biomarker-matched therapy but transitioned to chemotherapy or an ADC. Concurrent actionable alterations were uncommon. Among 12 patients with concurrent PI3K/AKT pathway and ESR1 alterations, four received PI3K/AKT-directed therapy only and three ESR1-directed therapy only. Among four patients with concurrent PI3K/AKT pathway and BRCA1/2 alterations, three received PI3K/AKT-directed therapy only, whereas none received a PARP inhibitor. No patient with concurrent actionable alterations in different pathways received more than one biomarker-matched therapy sequentially. Biomarker-guided therapies achieved median treatment durations ranging from 3.5 to 14.5 months and postponed the need for chemotherapy or antibody-drug conjugates (ADCs) by a median of 9 months. Conclusions: Molecular testing was implemented in a substantial proportion of patients with HR+/HER2− mBC and identified actionable alterations in the majority of tested patients. The use of biomarker-guided therapies delayed treatment escalation to chemotherapy or ADCs.
Related
- Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2− Metastatic Breast Cancer
- Molecular Biomarker Testing in Kidney Cancer: Integrating Diagnosis, Prediction, and Emerging Renal Tumor Entities
- Testing peripheral and central therapies for provoked vestibulodynia: results from the UPDATe trial
- Impact of traditional Chinese medicine combined with conventional therapies on the survival of patients with metastatic prostate cancer: a retrospective observational cohort study.
- CD38-targeted therapies in kidney disease: evidence maturity, disease-stage dependence, and biomarker-guided retreatment.
BibTeX
@article{deutschmann2026realworld,
title = {{Real-World Implementation of Molecular Testing and Biomarker-Guided Therapies in HR+/HER2− Metastatic Breast Cancer}},
author = {Christine Deutschmann and Matthias Filipovic and Dagmar Baha and Leonhard Müllauer and Zsuzsanna Bago-Horvath and Daphne Gschwantler-Kaulich and Georg Pfeiler and Carmen Leser and Christian F. Singer},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18213482},
url = {https://www.mdpi.com/2072-6694/18/21/3482},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-World Implementation of Molecular Testing and Biomarker-Guided Therapies in HR+/HER2− Metastatic Breast Cancer
AU - Christine Deutschmann
AU - Matthias Filipovic
AU - Dagmar Baha
AU - Leonhard Müllauer
AU - Zsuzsanna Bago-Horvath
AU - Daphne Gschwantler-Kaulich
AU - Georg Pfeiler
AU - Carmen Leser
AU - Christian F. Singer
PY - 2026
DA - 2026/10/28
JO - Cancers
DO - 10.3390/cancers18213482
UR - https://www.mdpi.com/2072-6694/18/21/3482
AB - Background/Objectives: The introduction of biomarker-guided therapies, including PI3K, AKT and PARP inhibitors as well as Selective Estrogen Receptor Degraders (SERDs), has expanded treatment options and delayed the need for chemotherapy in hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC). Nevertheless, evidence regarding their implementation in routine clinical practice remains limited. This study evaluated the real-world use of molecular testing and biomarker-guided therapies in patients with HR+/HER2− mBC. Methods: Patients with HR+/HER2− mBC treated at the Medical University of Vienna, Austria, between July 2020 (EMA approval of alpelisib, marking the introduction of biomarker-guided therapies in HR+/HER2− mBC) and April 2025 were identified through a retrospective chart review. Patient and disease characteristics, molecular testing patterns, utilization of biomarker-guided therapies, and oncological outcome were assessed. Biomarker-guided therapies included alpelisib and capivasertib for PI3K/AKT pathway alterations, elacestrant for ESR1 mutations, and PARP inhibitors for BRCA1/2 mutations. Descriptive statistics summarized patient characteristics, molecular testing, and biomarker-guided therapies. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and prognostic factors were evaluated using univariable and multivariable Cox regression analyses. Results: A total of 274 patients with HR+/HER2− mBC were included. 63.5% (174/274) of patients had undergone at least one molecular test. Overall, 59.8% (104/174) of patients harbored at least one actionable molecular alteration. Of these, 54.8% (57/104) received a biomarker-matched therapy. Of the 47 patients who had not received a matched therapy, 25 remained on first-line CDK4/6 inhibitor-based treatment and were therefore not yet candidates for subsequent biomarker-guided therapy. 12.8% (6/47) of patients with a targetable alteration did not receive a biomarker-matched therapy but transitioned to chemotherapy or an ADC. Concurrent actionable alterations were uncommon. Among 12 patients with concurrent PI3K/AKT pathway and ESR1 alterations, four received PI3K/AKT-directed therapy only and three ESR1-directed therapy only. Among four patients with concurrent PI3K/AKT pathway and BRCA1/2 alterations, three received PI3K/AKT-directed therapy only, whereas none received a PARP inhibitor. No patient with concurrent actionable alterations in different pathways received more than one biomarker-matched therapy sequentially. Biomarker-guided therapies achieved median treatment durations ranging from 3.5 to 14.5 months and postponed the need for chemotherapy or antibody-drug conjugates (ADCs) by a median of 9 months. Conclusions: Molecular testing was implemented in a substantial proportion of patients with HR+/HER2− mBC and identified actionable alterations in the majority of tested patients. The use of biomarker-guided therapies delayed treatment escalation to chemotherapy or ADCs.
SN - 2072-6694
ER -